Longevity Health Holdings (XAGE)

Longevity Health Holdings—operating under the ticker XAGE on the OTC Markets after trading on Nasdaq—is a small-scale healthcare company betting that the future of longevity lies in understanding and reversing the cellular damage that drives aging. Unlike pharmaceutical giants targeting individual diseases, Longevity frames its mission more broadly: helping people live longer and healthier through a combination of regenerative skincare, cutting-edge diagnostic tests, and emerging plasma-derived therapeutics.

The company’s origin reflects a common path in biotech: a platform technology looking for its commercial purpose. What began as Carmell Therapeutics—focused on allogeneic plasma-derived growth factors as a bone and soft tissue treatment—has evolved, through successive acquisitions and rebranding, into a portfolio company spanning consumer beauty, clinical diagnostics, and plasma collection operations. This pivot from specialized biotech to multi-channel health longevity is the heart of what Longevity is trying to become.

The Carmell Secretome and Plasma-Derived Beauty

At the center of Longevity’s consumer business sits the Carmell Secretome, a proprietary formulation extracted from banked human platelets. Unlike traditional platelet-rich plasma (PRP) treatments, which require a patient’s own blood draw and on-site processing, the Carmell Secretome uses pooled allogeneic (non-self) donor platelets. This means the product can be manufactured off-the-shelf, quality-controlled in bulk, and shipped as a finished cosmetic. The secretome contains over 1,000 growth factors, proteins, and peptides—the molecular signals that trigger skin repair and regeneration—without live cells.

The company packages this into topical skincare and haircare lines marketed to consumers seeking clinical efficacy without prescription barriers. A key competitive claim is that off-the-shelf allogeneic secretomes sidestep the regulatory and logistics complexity of autologous PRP while maintaining bioactivity. Whether that claim holds true in the market remains to be seen; the product is relatively young in commercial scale.

Exosomes and the Elevai Platform

In late 2024, Longevity acquired Elevai Skincare, a physician-dispensed skincare line built around exosomes derived from human stem cell culture. Exosomes are tiny extracellular vesicles that carry bioactive molecules and are believed to trigger cellular communication and regeneration. Where the Carmell Secretome leans on harvested plasma factors, Elevai offers an exosome-based alternative. The acquisition brought roughly $2.5 million in annual revenue and a complementary technology—essentially two different molecular strategies for the same anti-aging skincare market.

This layering of platforms (secretomes and exosomes) within the same company suggests Longevity is hedging its bets on which regenerative modality will resonate with consumers and clinicians, or whether there is room for both.

The Pivot to Diagnostics: 20/20 BioLabs

In mid-2025, Longevity announced an acquisition of 20/20 BioLabs, a diagnostics company whose flagship product is OneTest™—a multi-cancer early detection (MCED) blood test capable of identifying over a dozen tumor types from a single blood draw, priced below $200. A blinded study by the U.S. National Cancer Institute found that OneTest™ detected many cancer types at earlier stages than competing MCEDs, a competitive advantage in a nascent but rapidly growing market.

The merger positions diagnostics as a core pillar—moving Longevity from “beauty and wellness” into early disease detection, the most capital-intensive and regulated segment of its portfolio.

This acquisition marks a strategic turn. OneTest™ operates in a CLIA-licensed and CAP-accredited laboratory and has already begun integrating its tests into workplace wellness programs for firefighters and military veterans. A forthcoming “longevity test” aims to measure inflammatory markers tied to aging and disease risk. This is not cosmetics; it is clinical diagnostics, bringing regulatory complexity, reimbursement questions, and higher stakes.

The company has also piloted OneTest™ in partnership with Giant Food, hinting at retail pharmacy distribution—a distribution channel that could scale volume rapidly if clinical evidence and reimbursement align.

Plasma Collection: The THPlasma Integration

In July 2025, Longevity announced a merger agreement with THPlasma (True Health Inc.), a participant in the plasma collection and donation industry. This move is strategic: as the company scales its plasma-derived products (Carmell Secretome) and integrates plasma-derived therapeutics, owning or integrating a source of fresh plasma becomes operationally valuable. THPlasma operates collection centers and brings existing plasma supply relationships. The merger was anticipated to close in the fourth quarter of 2025.

On the surface, this looks like vertical integration—controlling supply of a critical raw material. But plasma collection is also a standalone recurring revenue business, with donors compensated per donation. For a small-cap healthcare company burning cash on R&D and acquisitions, a stable revenue stream from a tangential but related business can fund operations.

Capital and Scale Challenges

The company’s path has been one of rapid acquisition and integration. In 2023, it merged with Alpha Healthcare Acquisition Corp. III (a special-purpose acquisition company, or SPAC) to go public under the CTCX ticker. It then rebranded to XAGE in early 2025, signaling a shift from the Carmell Therapeutics identity to a broader longevity platform narrative. By 2025, the company faced stock price pressure and conducted a 1-for-30 reverse stock split to maintain Nasdaq listing compliance.

Revenue scaled from approximately $3–4 million to anticipated $7–8 million in 2025, a meaningful but still small absolute scale. The company has relied on equity offerings to fund operations and acquisitions; in May 2025, it raised $1.96 million through an at-the-market equity offering. Each capital raise dilutes existing shareholders and signals that the company is not yet cash-flow positive from operations.

The Longevity Thesis

Longevity Health Holdings is attempting to assemble a longevity platform from adjacent pieces: anti-aging skincare powered by plasma, exosome-based regeneration, cancer early detection, and plasma supply. The logic is that these segments are complementary—someone interested in aesthetic longevity is also a candidate for early disease screening, and the ability to supply one’s own raw materials (plasma) improves margins and supply security.

The risk is that the company is small, capital-intensive, and operating in multiple competitive markets (beauty, diagnostics, plasma supply) without clear dominance in any. Plasma-derived cosmetics face skepticism from consumers unfamiliar with the technology. Multi-cancer early detection tests face reimbursement headwinds and competition from larger diagnostics incumbents. Plasma collection is mature and consolidated. Executing across all three fronts simultaneously requires both capital and managerial bandwidth.

How to Research Longevity Health Holdings

The 10-K annual report filed with the SEC (CIK 1842939) is the primary source for understanding revenue mix, acquisition terms, and cash burn. Recent 8-K filings detail the 20/20 BioLabs and THPlasma mergers and their financial terms. For clinical validation of OneTest™ and other diagnostic claims, the company’s press releases reference published studies and the National Cancer Institute findings; those peer-reviewed sources are worth examining in detail. Earnings calls (when available) are rare for micro-cap OTC stocks, so written filings are the best window into management’s strategic thinking and operational execution. Watch for margin trends as the company scales diagnostics and plasma operations—profitability, not just revenue growth, determines whether these acquisitions prove accretive.